Creative Medical Technology Holdings Inc (CELZ)
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company focused on developing biological therapeutics across immunotherapy, endocrinology, urology, neurology, and orthopedics. The company markets CaverStem for erectile dysfunction and FemCelz for female sexual function concerns, including loss of genital sensitivity and dryness. Its development pipeline includes AlloStem (CELZ-201-DDT), ImmCelz (CELZ-100), and several other programs such as CELZ-201 CREATE-1 for type 1 diabetes and AlloStemSpine (CELZ 201 ADAPT) for chronic lower back pain. Additional product candidates and platforms address infertility linked to premature ovarian failure, degenerative disc disease, and other indications such as organ transplant rejection, kidney failure, liver failure, heart attack, and Parkinson’s disease. The company is based in Phoenix, Arizona, and its common stock trades on NASDAQ under the symbol CELZ.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CELZ
|
$1.17
|
20.7% Upside
|
Undervalued
|
$20 1,970.4% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
December 2, 2026
|
0.7x
|
2,122.8x
|
6.322 M
|
-2.432 M
|
0.2%
|
99.5%
|
-8.9
|
97.7%
|
